ALK3 (BMPR1A) siRNA Set I(B04-911)
FOR BULK ORDER REQUESTS PLEASE CONTACT US
Description :ALK3 (BMPR1A) is a pool of three individual synthetic siRNA duplexes designed to knock-down human ALK3 (BMPR1A) mRNA expression. Each siRNA is 19-25 bases in length.
Specificity :ALK3 (BMPR1A) siRNAs are designed to specifically knock-down human ALK3 (BMPR1A) expression.
Reconstitution Protocol :Each siRNA duplex is supplied as 2.5nmol per tube (for example 6 x 2.5nmol = 3 x 5nmol per duplex). Briefly centrifuge one tube per duplex (maximum RCF 4,000g) to collect lyophilized siRNA at the bottom of the tube. Resuspend each 2.5nmol tube in 50 ul of DEPC-treated water (included in kit), which results in a 1x stock solution (50 uM). Gently pipet the solution 3-5 times to mix and avoid the introduction of bubbles. Optional: aliquot 1x stock solutions for storage.
Storage and Stability :The lyophilized powder is stable for at least 4 weeks at room temperature. It is recommended that the lyophilized and resuspended siRNAs are stored at or below -20oC. After resuspension, siRNA stock solutions ≥2 uM can undergo up to 50 freeze-thaw cycles without significant degradation. For long-term storage, it is recommended that the siRNA is stored at -70oC. For most favorable performance, avoid repeated Handling and multiple freeze/thaw cycles.
Format :Lyophilized powder
Gene Aliases :ALK3; BMPR1A; 10q23del; ACVRLK3; CD292; SKR5
Scientific Background :BMPR1A (also known as bone morphogenetic protein receptor 1A) is a member of the transmembrane serine/threonine kinase family that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. BMPR1A act as a minor susceptibility gene for PTEN-mutation-negative Cowden syndrome. BMPR1A regulates the PTEN protein levels by decreasing PTEN's association with the degradative pathway (1). BMPR1A trafficking plays a significant role in FOP pathogenesis and is also involved in human T-cell differentiation (2)
1. Waite, K. A. et.al: BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum. Molec. Genet. 12: 679-684, 2003.
2. Cejalvo, T. et.al: Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development. Immunology 121: 94-104, 2007.
Product Sheets (By Lot #) :
Research Areas :AKT/PKB Pathway, Angiogenesis, Cancer, Cardiovascular Disease, JAK/STAT Pathway, Neurobiology, Ser/Thr Kinases, Cancer, Neurobiology, Cardiovascular Disease, AKT/PKB Pathway, JAK/STAT Pathway, Angiogenesis, Ser/Thr Kinases